Special Issue "Advances in Anti-Influenza Therapeutics"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: 31 July 2019
The influenza virus (flu) is a major cause of viral respiratory infections and is responsible for an enormous public socio-economic impact. The WHO estimates that annual influenza epidemics result in 3 to 5 million severe illnesses, approximately 300,000 to 650,000 deaths, and a large global economic impact. The high rates of morbidity and mortality caused by flu epidemics can dramatically increase during severe pandemic outbreaks.
Vaccination remains the main prophylactic strategy for controlling flu infection, but a universal flu vaccine that confers broad and long-term protection does not exist. Regarding the therapeutic armamentarium, almost 20 years from the approval of the neuraminidase (NA) inhibitors oseltamivir and zanamivir, they remain the only antiviral drugs of wide clinical use. The emergence of widespread resistance has caused M2 ion channel inhibitors to no longer be recommended, and the two recently approved NA inhibitors have important limitations. Nevertheless, during recent years, major breakthroughs have been made in the development of new anti-flu agents endowed with a different mode of action. Several agents have entered the clinical pipeline, many of which target the viral hemagglutinin and polymerase complex. Noteworthy are the compounds targeting the three subunits of the viral polymerase complex, such as the nucleoside analog favipiravir already approved in Japan, the PA endonuclease inhibitor baloxavir marboxil just approved in both Japan and the USA, and the PB2 cap-binding inhibitor pimodivir that is in late-phase clinical trials.
To achieve a comprehensive understanding of the progress made and the current trends in the development of new anti-flu therapeutics, the journal Pharmaceuticals invites renowned experts in the field to contribute research articles or reviews. This Special Issue, entitled Advances in Anti-Influenza Therapeutics, will focus on the development of new anti-flu agents, but also on studies aimed at understanding the molecular mechanisms of flu replication that are essential in order to identify new therapeutic targets.
Dr. Serena Massari
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 850 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- influenza virus
- anti-influenza agents
- drug discovery
- drug development